CYP11B2: Cytochrome P450 11B2, mitochondrial
A cytochrome P450 monooxygenase that catalyzes the biosynthesis of aldosterone, the main mineralocorticoid in the human body responsible for salt and water homeostasis, thus involved in blood pressure regulation, arterial hypertension, and the development of heart failure.
- Drugs that act on it: 1
- Approved: 1
- In phases 1 to 3: 0
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on CYP11B2, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| LevoketoconazoleBoxed warning | Approved | Strongbridge | Small molecule | InhibitorCytochrome P450 11B2 inhibitor | 0 |
- Corticosterone methyloxidase type 2 deficiency0.77
- Familial hypoaldosteronism0.56
- Steroid inherited metabolic disorder0.50
- Cushing syndrome0.49
- Early-onset familial hypoaldosteronism0.44
- Glucocorticoid-remediable aldosteronism0.43
- Familial hyperreninemic hypoaldosteronism type 20.40
- Adrenal gland hyperfunction0.37
- Adrenal gland disorder0.37
- Type 2 diabetes mellitus0.22
- Hereditary disease0.19
- Hypertensive disorder0.16
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2722, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P19099, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets